NCT06248515

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

A Phase II Parallel Arm Study of SACITUZUMAB GOVITECAN-HZIY in Patients With Advanced Thymoma and Thymic Carcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Georgetown University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therapy. The main question it aims to answer is: • What is the overall response rate (ORR) in patients with advanced thymoma and thymic carcinoma? Participants will: * receive a fixed dose of 10 mg/kg given intravenously, once weekly on Days 1 and 8 of continuous 21-day treatment cycles until disease progression or unacceptable toxicity * have regular blood tests, scans, and examinations to monitor their health. * have blood and a biopsy of their tumor for research purposes.

Conditions

• Thymoma
• Thymic Carcinoma

Interventions

Type	Name	Description
DRUG	Sacituzumab govitecan-hziy	10 mg/kg once weekly on Days 1 and 8 of continuous 21-day treatment cycles

Timeline

• Start date: 2024-04-25
• Primary completion: 2026-04-01
• Completion: 2026-12-01
• First posted: 2024-02-08
• Last updated: 2026-01-27

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study